Gland Pharma Ltd. (GLAND) AI Stock Analysis

• Market Cap: ₹322.63B
• Dividend Yield: 0.92%
• Average Volume (3M): 11.04K
• Price to Earnings (P/E): 41.9
• Beta (1Y): 0.44
• Revenue Growth: -2.34%
• EPS Growth: 6.64%
• Country: IN
• Employees: 4,217
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - General
• EPS (TTM): 13.08
• Shares Outstanding: 164,756,420
• 10 Day Avg. Volume: 5,475
• 30 Day Avg. Volume: 11,043
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,910.29
• Price Target Upside: -2.45% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 7

• Rating: 68 Neutral
• Price Target: ₹2,292.00 ▲(17.05% Upside)

Gland Pharma Ltd. demonstrates strong financial performance with efficient cash flow management and a robust balance sheet. However, technical analysis indicates potential overbought conditions, and the stock's high P/E ratio suggests it may be overvalued. The combined factors result in a balanced overall score.

Gland Pharma Ltd. Business Overview & Revenue Model

Company Description

Gland Pharma Ltd. (GLAND) is an Indian pharmaceutical company that specializes in the production of injectable products. Established in 1978, the company is known for manufacturing a wide range of complex injectables, including biosimilars, peptides, and long-acting injectables. It operates across various therapeutic areas such as anti-infectives, oncology, and cardiovascular, providing products that cater to both regulated and emerging markets.

How the Company Makes Money

Gland Pharma Ltd. generates revenue primarily through the manufacturing and sale of injectable pharmaceutical products. The company serves a diverse clientele, including hospitals, clinics, and pharmaceutical companies around the world. A significant portion of its income is derived from export sales to highly regulated markets like the United States, Europe, Canada, and Australia, where it supplies both generic injectables and contract manufacturing services. Additionally, the company partners with other pharmaceutical companies for co-development and out-licensing agreements, further enhancing its revenue streams. Its earnings are bolstered by its focus on producing complex and high-value products, which allows it to maintain competitive pricing and secure long-term contracts.

Gland Pharma Ltd. Financial Statement Overview

Summary

Gland Pharma Ltd. shows strong financial health with consistent revenue growth, solid profitability metrics, and a robust balance sheet. While there are concerns regarding recent declines in net income and free cash flow growth, overall financial management remains efficient.

Income Statement

Gland Pharma Ltd. has shown consistent revenue growth over the years, although there was a slight dip in 2025. The company maintains strong gross and net profit margins, with EBIT and EBITDA margins indicating efficient operational management. However, the recent decline in net income may point to potential challenges in maintaining profit margins.

Balance Sheet

The company demonstrates a robust balance sheet with a strong equity base and a low debt-to-equity ratio, indicating low financial leverage and risk. The equity ratio is solid, reflecting financial stability and a healthy capital structure. However, the slight increase in total liabilities over the years requires monitoring.

Cash Flow

Operating cash flow remains strong, supporting the company's ability to fund operations. The free cash flow is positive, though it has shown some fluctuations. The cash flow ratios suggest efficient cash management, yet the decrease in free cash flow growth rate in recent years could indicate challenges in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2020
Income Statement
Total Revenue	56.17B	56.17B	56.42B	43.84B	36.25B	25.72B
Gross Profit	25.11B	33.27B	30.88B	22.75B	19.39B	14.70B
EBITDA	14.37B	12.69B	15.03B	17.34B	12.09B	10.95B
Net Income	6.99B	6.99B	7.72B	12.12B	7.81B	7.73B
Balance Sheet
Total Assets	112.25B	112.25B	106.61B	78.34B	87.78B	40.86B
Cash, Cash Equivalents and Short-Term Investments	30.50B	30.50B	19.39B	32.43B	38.36B	13.12B
Total Debt	3.14B	3.14B	3.72B	47.43M	44.53M	60.11M
Total Liabilities	20.74B	20.74B	19.37B	6.76B	8.19B	4.40B
Stockholders Equity	91.51B	91.51B	87.24B	71.58B	79.59B	36.46B
Cash Flow
Free Cash Flow	0.00	5.30B	5.99B	2.69B	1.41B	5.06B
Operating Cash Flow	0.00	9.15B	9.97B	7.91B	3.64B	7.01B
Investing Cash Flow	0.00	17.05B	-17.57B	-10.03B	12.08B	-7.66B
Financing Cash Flow	0.00	-4.33B	-7.99B	348.98M	149.19M	-68.71M

Gland Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1958.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAND, the sentiment is Positive. The current price of 1958.2 is below the 20-day moving average (MA) of 1967.75, above the 50-day MA of 1890.75, and above the 200-day MA of 1671.27, indicating a neutral trend. The MACD of 13.61 indicates Positive momentum. The RSI at 54.52 is Neutral, neither overbought nor oversold. The STOCH value of 52.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GLAND.

Gland Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DRREDDY	74 Outperform	₹1.07T	18.75		0.62%	15.86%	2.02%
SUNPHARMA	73 Outperform	₹3.94T	38.00		0.97%	9.28%	-0.17%
TORNTPHARM	73 Outperform	₹1.25T	62.29		0.87%	7.63%	15.39%
AUROPHARMA	71 Outperform	₹609.99B	17.99		0.38%	7.76%	-2.84%
GLAND	68 Neutral	₹322.63B	41.89		0.92%	-2.34%	6.64%
GLAXO	65 Neutral	₹474.25B	49.91		1.93%	6.65%	48.47%
Sector *	51 Neutral	$7.89B	-0.12	-39.89%	2.16%	21.38%	-1.56%

Gland Pharma Ltd. Corporate Events

Gland Pharma Updates RTA Contact Details Following Rebranding

Gland Pharma Limited has announced a change in the contact details of its Registrar and Share Transfer Agent (RTA) due to a rebranding from ‘Link Intime India Private Limited’ to ‘MUFG Intime India Private Limited’. This update is crucial for shareholders and stakeholders who need to interact with the RTA for queries or service requests, ensuring continued smooth operations and communication.